Trial Profile
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms LIBERTY-UC SUCCEED
- Sponsors Sanofi
- 20 Feb 2023 New trial record